Diabetic Macular Edema

The number of anti-VEGF injections patients underwent per 28 days decreased from 0.322 to 0.047 after FAc implantation.

Researchers found testing is significantly more practiced by patients offered it in person, versus those referred, with little difference found in mutation identification.

Though cell therapies have gained FDA approval to treat any ocular disease, companies have marketed predominately to patients with AMD, with procedures that could lead to blindness.

Though the 2 dosing regimens had comparable visual acuity improvements over 24 months, patients given ranibizumab once-monthly received treatment nearly 6 more times on average.

The treatment, traditionally used for cancer, not only improved BVCA measurements but also resulted in the number of injections patients needed.

At the final follow-up in year 5, 16.5% of eyes had lost >15 ETDRS letters, compared to 33% that had gained >15 ETDRS letters.

Researchers found that, contrary to popular opinion, about 80% of patients are receiving at least 7 dosing regimens of anti-VEGF in their first year of treatment, and that frequency has been proven to improve visual acuity.

The analysis suggests that patients with neovascular AMD may be undertreated in clinical practice settings.

The FDA has granted a breakthrough therapy for atezolizumab Tin combination with bevacizumab for the treatment of advanced or metastatic hepatocellular carcinoma.

The first meta-analysis of AMD clinical meta-analyses shows many have methodological limitations—more so those sponsored by industry than those sponsored by governments.

Researchers suggested that anti-oxidants such as Vitamin C and E could delay or even reduce the risk of AMD in patients with gout, as they have been proven to have a beneficial effect in patients with AMD.

Emixustat has been shown in previous preclinical analysis to slow the visual cycle and inhibit the activity of RPE65 and associated loss of photoreceptors associated with RPE dysfunction.

To the knowledge of researchers, this is the first demonstration to show C3a can stimulate basal deposit production by normal human RPE cells.

Utilizing research from the Age-Related Eye Disease Study 2, researchers found that MA and GA may be part of the same disease process affecting the visual acuity of patients with AMD.

In an invited commentary, a trio of authors called the concept of improving or protecting visual function as a viable intervention to prevent or control cognitive decline overall both “plausible and attractive.”

Evidence determines that those receiving treatment for nAMD should delay cataract surgery within 6 months of starting treatment, if possible.

Despite having worse vision and more CST than participants without baseline MNP upon entering the trials, patients experienced increased visual acuity along with improvements in anatomy.

Importantly, they are not directed toward ophthalmologists, but at general physicians and public healthcare professionals.

The findings present the first assessment of peripheral changes in AMD and time to dark-adapt and could establish DA as a promising functional outcome measure in AMD.

It is the first approval of a product for this indication and is now available on Optovue’s Avanti Widefield optical coherence tomography system.

Children with amblyopia and strabismus took roughly 28% longer than their peers when transferring answers to a multiple-choice answer form, despite having good vision in 1 or both eyes.

The FDA has approved bevacizumab for patients with ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for either stage 3 or 4 disease after initial surgical resection.

The survey revealed that 89% of practitioners said that their patients use screens for fewer than 10 hours each day, despite 33% of adults reporting passing that mark.

Most patients, whether or not they had preoperative fluid, saw improved BCVA post-surgery, and there were no significant differences in central subfield thickness.

Researchers aimed to determine how prophylactic, topical NSAIDs affected the development of CME, specifically ketorolac tromethamine 0.4% and nepafenac 0.1%.

The model was tested using 402 normal and 708 AMD color fundus images, achieving a 95.45% average accuracy with a 10-fold cross validation strategy and a 91.17% average accuracy with blindfold validation.

Study results show that OHTN may be an early biomarker of hypertension and may herald risk of developing AMD, and perhaps, other conditions caused by vascular disease.

Diabetes causes ELOVL4 to be downregulated, weakening the tight junctions. Researchers hope that replacing these lipids could be a treatment for diabetic retinopathy.

Researchers predicted that the inclusion of these additional factors—such as DME or RVO, and Medicare Advantage plan or private insurance use—would see cost savings in excess of $30 billion.

The researchers hope they will be able to use this template as a drug delivery solution for a variety of eye diseases.